[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"University of British Columbia\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":679},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,189,0,25,[9,42,69,102,131,159,185,213,241,282,303,330,355,382,401,426,453,480,509,531,555,581,607,631,655],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":26,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100645853","brain-based-prediction-of-the-dying-duration-in-humans-after-withdrawal-of-life-sustaining-therapies-to-inform-donation-after-circulatory-death-100645853",false,"NCT07698262","Brain-based Prediction of the Dying Duration in Humans After Withdrawal of Life Sustaining Therapies to Inform Donation After Circulatory Death","NeuroDCD","Inclusion Criteria:\n\n1. Age ≥ 19;\n2. Eligible for DCD\n\nExclusion Criteria:\n\n1. Complete high cervical spinal cord injury (C5 and above)\n2. Pacemaker in situ\n3. Tracheostomy","ALL","19 Years",{"count":20,"type":21},102,"ESTIMATED","OBSERVATIONAL","The purpose of this study is to develop a new tool that uses information collected before life-sustaining treatments are withdrawn to better predict whether a patient will die within the time needed for organ donation to be possible. The tool created should help improve planning for organ donation and provide families and healthcare teams with more accurate information.",[25],"Organ Donation After Circulatory Death",[27,28],"Predicting organ donation after circulatory death","DCD","NOT_YET_RECRUITING","2026-08-20",{"date":32,"type":33},"2026-08-21","ACTUAL",{"date":35,"type":21},"2027-01",{"date":37,"type":21},"2030-12",{"name":39,"class":40},"University of British Columbia","OTHER",11,{"id":43,"slug":44,"hasResults":12,"nctId":45,"briefTitle":46,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":12,"sex":49,"minAge":50,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":53,"phases":54,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":68},"100424858","phase-2-genomic-biomarker-selected-umbrella-neoadjuvant-study-for-high-risk-localized-prostate-cancer-100424858","NCT04812366","Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate Cancer","GUNS","Inclusion Criteria:\n\ni. Males ≥ 18 years of age. ii. Histologically confirmed adenocarcinoma of the prostate without pathologic evidence of small cell differentiation at the time of initial diagnosis. Screening biopsy must be performed within 4 months of the screening visit.\n\niii. High-risk localized prostate cancer as defined by at least one of the following:\n\n* Any combination of Gleason Score 4+3=7 and Gleason Score 8 (4+4 or 5+3) in ≥6 systematic cores (with ≥1 core Gleason Score 8 \\[4+4 or 5+3\\] included);\n* Any combination of Gleason Score 4+3 and Gleason Score 8 (4+4 or 5+3) in ≥3 systematic cores and PSA ≥20 ng\u002FmL (with at least 1 core Gleason Score 8 \\[4+4 or 5+3\\] included);\n* Gleason Score ≥9 in at least 1 systematic or targeted core;\n* At least 2 systematic or targeted cores with Gleason Score ≥8, each with at least 80% involvement\"; or\n* Gleason Score 4+3=7 in at least 6 systematic or targeted cores and PSA ≥20 ng\u002FmL iv. Participants must provide consent blood collection and evaluation of diagnostic prostate tissue for genetic testing at registration and prior to assignment by a central reference laboratory.\n\n  v. No prior systemic or localized treatment for prostate cancer (exception: up to 12 weeks of luteinizing hormone-releasing hormone agonist or antagonist (LHRHa) and bicalutamide is allowable prior to registration).\n\nvi. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 (Appendix II) and a life expectancy of ≥ 3 years in the opinion of the treating oncologist.\n\nvii. Laboratory Requirements: Participants must have adequate end-organ function and all laboratory tests must be performed within 8 weeks prior to registration into master protocol (Table 1).\n\nviii. Patient consent must be appropriately obtained in accordance with applicable local and regulatory requirements. Each patient must sign a consent form prior to registration in the trial to document their willingness to participate.\n\nix. Archival tissue must be available for genetic analysis.\n\nExclusion Criteria:\n\nParticipants will be excluded if ANY of the following criteria are met:\n\ni. Received more than 12 weeks of LHRHa prior to registration. ii. Stage T4 prostate cancer by clinical examination or radiologic evaluation. iii. Hypogonadism or severe androgen deficiency as determined by the treating physician, or screening serum testosterone less than 50 ng\u002FdL (1.7 nmol\u002FL) iv. Participants with serious illnesses or medical conditions which could cause unacceptable safety risks or would not permit the participant to be managed according to the protocol. This includes but is not limited to:\n\n* Active infection or chronic liver disease requiring systemic therapy;\n* Active or known human immunodeficiency virus (HIV) with detectable viral load;\n* Participants with uncontrolled hypertension or diabetes.\n* Uncontrolled or recent clinically significant cardiac disease, including history of any of the following within 12 months prior to screening:\n\n  * Severe or unstable angina, symptomatic pericarditis, symptomatic congestive heart failure, arterial or venous thromboembolic events (e.g., pulmonary embolism, cerebrovascular accident including transient ischemic attacks), clinically significant ventricular arrhythmias or New York Heart Association Class II to IV heart disease, coronary artery bypass grafting, coronary angioplasty, stenting, or myocardial infarction; uncomplicated deep vein thrombosis is not considered exclusionary).\n  * History of any cardiac arrhythmias that preclude prostatectomy or treatment with study drugs, e.g. ventricular, supraventricular, nodal arrhythmias, or conduction abnormality.\n\n    v. Participants who are unable to swallow oral medication and\u002For have impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of the study drugs (e.g. ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or small bowel resection).\n\nvi. Participants with a history of hypersensitivity to any of the study drugs or any excipient.\n\nvii. Participants with a history of non-compliance to medical regimens. viii. Severe concurrent disease, infection, or co-morbidity that, in the judgment of the Investigator, would make the participant inappropriate for registration or prostatectomy.\n\nix. Prior androgen deprivation, chemotherapy, surgery, or radiation for prostate cancer.\n\nx. Receiving concurrent androgens, estrogens, or progestational agents, or received any of these agents within the 6 months prior to registration.\n\nxi. M1 by conventional imaging (CT, bone scan) or PSMA-PET. Participants with oligometastatic (\\\u003C3) metastases by PSMA imaging only who are deemed candidates for radical prostatectomy are eligible.","MALE","18 Years",{"count":52,"type":21},315,"INTERVENTIONAL",[55],"PHASE2","The objective of this study is to see if providing an appropriate therapy based on the genomic testing of prostate tumour tissue will result in an improved clinical response.\n\nEach participant will be treated with 8 weeks of a luteinizing hormone-releasing hormone agonist (LHRHa) plus apalutamide (APA) while genome sequence characterization is being done. Participants with biopsy specimens deemed unevaluable for genomic testing will remain on LHRHa plus APA for an additional 16 weeks.\n\nParticipants with evaluable tissue will be assigned to one of the open-label sub-studies on the basis of genomic profiling results. Within each group, they will be randomized to a specific treatment arm either LHRHa plus APA alone or adding abiraterone acetate and prednisone, docetaxel or niraparib.\n\nThe study will evaluate the response rate and outcomes after radical prostatectomy in each arm of the trial.",[58],"Prostate Cancer","RECRUITING","2026-08-12",{"date":62,"type":33},"2026-08-14",{"date":64,"type":33},"2021-09-21",{"date":66,"type":21},"2027-06-01",{"name":39,"class":40},9,{"id":70,"slug":71,"hasResults":12,"nctId":72,"briefTitle":73,"officialTitle":73,"acronym":4,"eligibilityCriteria":74,"healthyVolunteers":12,"sex":17,"minAge":75,"maxAge":4,"enrollmentInfo":76,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":78,"conditions":79,"keywords":85,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":101},"100651507","reliability-in-neurocognitive-telemedicine-screening-ring-100651507","NCT07760545","Reliability In Neurocognitive Telemedicine Screening (RING)","Inclusion Criteria:\n\n1. Patients with age \\>65 at time of listing for pre-operative assessment.\n2. Patients with a conversational understanding of English language.\n3. Patients scheduled for in-person consult with an anaesthesiologist.\n4. Patients awaiting surgery at Vancouver General Hospital or University of British Columbia Hospital.\n\nExclusion Criteria:\n\n1\\. Patients with known cognitive impairment.","65 Years",{"count":77,"type":21},300,"Perioperative neurocognitive disorders are common after surgery and pre-existing cognitive impairment is an important risk factor. Current guidelines recommend identifying cognitive impairment before surgery; however, screening remains inconsistent, particularly when preoperative assessments are performed remotely.\n\nThis prospective observational diagnostic validation study aims to determine whether a modified Mini-Cog cognitive screening tool administered by telephone can reliably identify cognitive impairment in patients aged 65 years and older undergoing preoperative assessment. Telephone-based modified Mini-Cog results will be compared with standard in-person Mini-Cog assessments to evaluate agreement and feasibility. This study may improve access to preoperative cognitive screening and support optimization of surgical care for older adults.",[80,81,82,83,84],"Cognitive Impairment","Preoperative Cognitive Impairment","Perioperative Neurocognitive Disorders","Neurocognitive Function","Cognitive Screening",[86,87,88,89,90,91,92,93],"Perioperative neurocognitive disorders","Cognitive impairment","Preoperative cognitive screening","Cognitive assessment","Mini-Cog","Modified Mini-Cog","Telephone-based cognitive screening","Telemedicine","2026-08-07",{"date":60,"type":33},{"date":97,"type":33},"2023-05-02",{"date":99,"type":21},"2027-01-30",{"name":39,"class":40},1,{"id":103,"slug":104,"hasResults":12,"nctId":105,"briefTitle":106,"officialTitle":106,"acronym":107,"eligibilityCriteria":108,"healthyVolunteers":12,"sex":109,"minAge":18,"maxAge":4,"enrollmentInfo":110,"targetDuration":4,"studyType":53,"phases":112,"briefSummary":114,"conditions":115,"keywords":118,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":123,"lastUpdatePostDateStruct":124,"startDateStruct":126,"completionDateStruct":128,"leadSponsor":130,"locationsCount":101},"100650479","implementing-virtual-reality-exposure-therapy-for-vaginismus-from-efficacy-to-clinical-integration-vivid-3-100650479","NCT07747298","Implementing Virtual Reality Exposure Therapy for Vaginismus: From Efficacy to Clinical Integration (VIVID 3)","VIVID 3","Inclusion Criteria:\n\n* Diagnosis of vaginismus defined by a \"marked fear or anxiety about vulvovaginal or pelvic pain in anticipation of, during, or because of vaginal penetration\" (criterion from the DSM-5 definition of Genito-Pelvic Pain Penetration Disorder)\n* Aged \\>19 y, of any sexual orientation\n* Fluent in English (psychoeducational materials and questionnaires delivered in English)\n* Normal or corrected-to-normal vision (to view the VR scenes during exposure)\n* Able to travel to Vancouver\n\nExclusion Criteria:\n\n* Presence of: unprovoked vaginal pain\n* Vulvar skin condition (i.e., lichen sclerosus)\n* Epilepsy characterized by photosensitive seizures.\n\nNote: provoked vulvar pain is not an exclusion criterion because at least 40% of people with vaginismus report pain with attempted penetration.","FEMALE",{"count":111,"type":21},167,[113],"NA","Vaginismus, a condition characterized by involuntary tightening of the pelvic floor muscles due to strong fear of vaginal insertion, impact ≥6% of the female population and can make vaginal intercourse and medical exams difficult. This project explores virtual reality exposure (VRE) as a new treatment approach. Building on our two previous studies showing that VRE is feasible and effective in helping patients to gradually face feared sexual encounters in a virtual environment, we aim to implement our VRE protocol at the BC Centre for Vulvar Health (BCCVH). We will assess barriers\u002Ffacilitators to implementation, clinician uptake, and patients' outcomes and engagement.",[116,117],"Vaginismus","Difficulties With Vaginal Penetration",[119,120,121,122,116],"Virtual reality","Digital health","Sexual health","Implementation science","2026-07-30",{"date":125,"type":33},"2026-08-05",{"date":127,"type":21},"2026-09-01",{"date":129,"type":21},"2028-09-01",{"name":39,"class":40},{"id":132,"slug":133,"hasResults":12,"nctId":134,"briefTitle":135,"officialTitle":136,"acronym":137,"eligibilityCriteria":138,"healthyVolunteers":139,"sex":17,"minAge":50,"maxAge":4,"enrollmentInfo":140,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":142,"conditions":143,"keywords":145,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":123,"lastUpdatePostDateStruct":151,"startDateStruct":153,"completionDateStruct":155,"leadSponsor":157,"locationsCount":158},"100549925","small-steps-for-big-changes---healthy-cities-implementation-science-100549925","NCT06440395","Small Steps for Big Changes - Healthy Cities Implementation Science","Small Steps for Big Changes: Implementing an Evidence-Based Diabetes Prevention Program Into Diverse Urban Communities","HCIS","Patients\n\nInclusion Criteria:\n\n* Community-dwelling adults aged 18 years or older\n* able to read and speak English\n* has prediabetes assessed by one of the following means: (a) physician-diagnosed prediabetes, (b) HbA1c values between 5.7 - 6.4% (American Diabetes Association, 2012), (c) an American Diabetes Association risk questionnaire score indicating increased risk (\\>5)\n* Individuals who have previously been diagnosed with type 2 diabetes but who are in remission (defined as achieving glycated hemoglobin (A1C) of \\\u003C 6.4% without any diabetes-related medications for a minimum of 3 months) will be eligible to participate.\n\nExclusion Criteria:\n\n\\- Patients currently diagnosed type 2 diabetes with an HbA1c of 6.5% or greater.\n\nOrganizational partners\n\nInclusion criteria:\n\n\\- Senior leadership and\u002For management of our Canadian YMCA delivery partner organizations\n\nExclusion criteria: N\u002FA\n\nSite leads\u002Fmanagers\n\nInclusion criteria:\n\n\\- YMCA staff who manage\u002Fcoordinate programs (e.g., general manager of health programs) for each site willing to act as SSBC site lead champion.\n\nExclusion criteria: N\u002FA\n\nCoaches\n\nInclusion criteria:\n\nSite staff certified as SSBC coaches to deliver the program.\n\nExclusion criteria: N\u002FA",true,{"count":141,"type":21},4400,"Small Steps for Big Changes (SSBC) is a diet and exercise counselling program that significantly reduces the risk of developing Type 2 Diabetes (T2D). In partnership with YMCAs in Canada spanning 8 provinces, the aim of this study is to scale-up program delivery and evaluate the implementation and effectiveness of SSBC. To evaluate implementation, the number of staff trained\u002Fpatients enrolled, attendance, sessions delivered as planned, delivery costs, and number of sites continuing to deliver the program will be examined. To evaluate program effectiveness, changes in patient health (e.g., T2D status, blood glucose, weight, exercise, diet) will be measured over 2 years following program completion.",[144],"PreDiabetes",[146,147,148,149,150],"Implementation Science","Exercise Behaviour","Diet Behaviour","Adherence","Health Behaviour Change",{"date":152,"type":33},"2026-08-03",{"date":154,"type":33},"2024-06-03",{"date":156,"type":21},"2029-09",{"name":39,"class":40},12,{"id":160,"slug":161,"hasResults":12,"nctId":162,"briefTitle":163,"officialTitle":164,"acronym":165,"eligibilityCriteria":166,"healthyVolunteers":12,"sex":109,"minAge":18,"maxAge":4,"enrollmentInfo":167,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":169,"conditions":170,"keywords":172,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":178,"lastUpdatePostDateStruct":179,"startDateStruct":180,"completionDateStruct":182,"leadSponsor":184,"locationsCount":101},"100619157","sensory-stimuli-during-cesarean-delivery-100619157","NCT07340970","Sensory Stimuli During Cesarean Delivery","Patient Perception of Sensory Stimuli During Elective Cesarean Delivery Under Neuraxial Anesthesia (PIONEER): A Multicenter Prospective Cohort Study","PIONEER-MC","Inclusion Criteria:\n\n* Pregnant and 19 years of age or older\n* Single (one) baby at 37 weeks of pregnancy or later\n* Overall health classified as American Society of Anesthesiologists (ASA) Physical Status II or III\n* Scheduled for a planned (elective) cesarean delivery using spinal anesthesia (single-shot spinal or combined spinal-epidural)\n* Able to describe sensations in their own words in one of the study's available languages\n* Willing and able to give written informed consent before any study procedures\n* Willing and able to complete online follow-up questionnaires at 6 weeks, 3 months, and 6 months after delivery\n\nExclusion Criteria:\n\n* History of a chronic pain condition (for example, fibromyalgia, chronic pelvic pain, complex regional pain syndrome, or chronic low back pain requiring ongoing treatment)\n* Regular use of opioids, gabapentinoids (gabapentin or pregabalin), or other centrally acting pain medications during the current pregnancy (occasional acetaminophen use is allowed)\n* History of a neurological condition that can affect normal sensation (for example, peripheral neuropathy, multiple sclerosis, or spinal cord injury)\n* Pregnancy with more than one baby (twins or more)\n* Cesarean delivery planned with an anesthesia method other than single-shot spinal or combined spinal-epidural (for example, topping up an existing labor epidural, or general anesthesia)\n* Known major fetal abnormality or an expected newborn complication likely to require immediate admission to the neonatal intensive care unit (NICU)\n* Known allergy or other reason the local anesthetic medications used for spinal anesthesia cannot be given\n* Active substance use disorder",{"count":168,"type":21},1005,"During a cesarean delivery (C-section), most patients are awake and receive spinal or epidural anesthesia to block pain from the lower body. Even when this anesthesia works well, many patients still feel sensations during surgery, such as pulling, pressure, tugging, or, in some cases, pain. In the past, studies have mostly focused on whether patients felt \"pain,\" and have often relied on patients remembering their experience afterward or on the surgical team's judgment of how the patient was doing. These approaches can miss sensations that bother the patient but are not clearly described as pain, and they may not reflect what the patient actually wanted done at the time.\n\nThis study takes a different approach. Instead of asking only about pain, the researchers will ask patients, in real time during their C-section, what they are feeling in their own words, and whether they would like the medical team to do something about it (such as giving medication). The main idea is that the patient's own request for help, rather than someone else's opinion about how severe a sensation is, should be what counts as a moment that matters.\n\nThe main purpose of the study is to find out how often patients undergoing a planned C-section ask for medication in response to a sensation they feel during surgery. The researchers will ask each patient at six specific points during the operation whether they feel any sensation, how they would describe it, and whether they would like the team to act. Patients will also rate how strong each sensation is and point to where on the body they feel it. All decisions about care will remain entirely with the patient's own medical team; the research team only records what the patient reports and what care is given.\n\nThe study is also designed to answer several related questions:\n\n* What words and descriptions do patients naturally use for the sensations they feel during a C-section?\n* How often are sensations that patients do not call \"painful\" still bothersome enough that the patient asks for medication?\n* How do patients' feelings and mental health change over the first six months after delivery, including symptoms of post-traumatic stress, depression, and birth-related distress?\n* Does a patient's anxiety before surgery affect what they feel during surgery or how likely they are to ask for help?\n\nThe main question the study is trying to answer is: How often do patients undergoing a planned cesarean delivery ask for medication because of something they feel during the operation?\n\nThe researchers' hypothesis is that this number will be higher than what earlier pain-focused studies have reported. Specifically, they expect that more than 11.5 percent of patients will ask for medication during surgery, which is greater than the rate of pain requiring extra medication found in a similar previous study. If correct, this would suggest that the true number of patients who experience moments during a C-section when they want help has been underestimated by traditional methods that focus only on pain.\n\nThis is an observational study. It does not test a new drug or change how anesthesia or surgery is performed. Instead, it carefully observes and records patients' experiences in order to better understand what patients feel during a cesarean delivery, how often they want the team to act, and how these experiences relate to their recovery and emotional well-being afterward. The goal is to use this information to improve the comfort, care, and long-term well-being of patients having a C-section.",[171],"Intraoperative Pain",[173,174,175,176,177],"cesarean delivery","neuraxial anesthesia","intraoperative pain","intraoperative sensation","peritraumatic distress","2026-07-29",{"date":152,"type":33},{"date":181,"type":21},"2026-07-20",{"date":183,"type":21},"2027-09-30",{"name":39,"class":40},{"id":186,"slug":187,"hasResults":12,"nctId":188,"briefTitle":189,"officialTitle":190,"acronym":4,"eligibilityCriteria":191,"healthyVolunteers":139,"sex":17,"minAge":18,"maxAge":192,"enrollmentInfo":193,"targetDuration":4,"studyType":53,"phases":195,"briefSummary":197,"conditions":198,"keywords":200,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":181,"lastUpdatePostDateStruct":206,"startDateStruct":208,"completionDateStruct":210,"leadSponsor":212,"locationsCount":101},"100648008","early-phase-1-ivabradine-for-heart-rate-reduction-during-exercise-in-healthy-adults-100648008","NCT07717710","Ivabradine for Heart Rate Reduction During Exercise in Healthy Adults","Heart Rate Reduction Via Oral Ivabradine During Exercise in Healthy Adults to Understand Heart Rate\u002FWork-rate Relations: A Pilot Dose-selection Study","Inclusion Criteria:\n\n* Healthy males and females aged 19-39 years, and 60-79 years\n* Engaging in regular aerobic exercise (e.g., running, cycling, swimming, hiking, field, ice, or racquet sports) at least once per week\n\nExclusion Criteria:\n\n* History of any cardiovascular condition, including hypertension\n* Use of any chronic medication\n* History of any respiratory condition, including asthma\n* Smoking, including cannabis or vaping in the past year\n* History of diabetes mellitus, cancer, hepatic, renal or any other chronic illness\n* Seated blood pressure ≥130\u002F90 or \\\u003C100\u002F60 mmHg\n* Body mass index \\\u003C20 or \\>32 kg\u002Fm2\n* Non-sinus rhythm or abnormalities on 12-lead electrocardiogram (ECG)\n* Pregnant, breastfeeding, or women of childbearing potential not using appropriate contraception\n* Current or recent (past year) participation in \\>150 minutes per week of moderate-vigorous intensity exercise (to avoid endurance training-related bradycardia)\n* Any condition that prevents vigorous exercise from being performed safely\n* Seated resting heart rate \\\u003C60 beats per minute\n* Prolonged QT interval (e.g., long QT syndrome)\n* Sick sinus syndrome, sino-atrial block or third-degree atrio-ventricular block\n* Use of strong cytochrome P450 (CYP3A4) inhibitors (e.g., nirmatrelvir and ritonavir, ketoconazole), which can increase ivabradine levels in the blood to potentially unsafe levels\n* Use of verapamil or diltiazem, which are moderate CYP3A4 inhibitors and also lower heart rate, posing a risk of excessive bradycardia when combined with ivabradine\n* Lactose intolerance, as ivabradine contains lactose\n* Known allergy\u002Fhypersensitivity to ivabradine or to any ingredient in the formulation or component of the container","79 Years",{"count":194,"type":21},20,[196],"EARLY_PHASE1","During exercise, working muscles require more oxygen. The heart meets this demand in two ways: by beating faster (heart rate) and by pumping more blood with each beat (stroke volume). Heart rate increases steadily with exercise intensity until exhaustion, but the amount of blood pumped with each beat tends to plateau at moderate intensities. Why the amount of blood pumped with each beat becomes limited before heart rate, however, is not well understood.\n\nStudying these mechanisms is difficult because most drugs that lower heart rate also affect how strongly the heart pumps, making it hard to separate the two effects. One medication that can help with this is ivabradine, which is used to treat people with heart disease who have high resting heart rates. It slows the heart rate without changing how strongly the heart pumps.\n\nThis study will investigate whether ivabradine lowers heart rate during exercise in healthy younger and older adults, and whether a higher dose lowers heart rate more. The results will help us better understand how heart rate influences the heart's ability to supply oxygen to the body during exercise, and what limits the ability to exercise as people age.\n\nParticipants will:\n\n* Attend three visits at SportsCardiologyBC in Vancouver\n* Complete a cycling exercise test at each visit to measure heart rate and how hard they can exercise\n* Take ivabradine (a heart-rate-lowering medication) before the exercise test at Visits 2 and 3 (a lower dose at Visit 2 and a higher dose at Visit 3)\n* Be monitored for side effects including slow heart rate, visual symptoms, and headache.",[199],"Healthy Adult",[201,202,203,204,205],"Heart rate regulation","Stroke volume","Cardiac output","Exercise","Exercise capacity",{"date":207,"type":33},"2026-07-22",{"date":209,"type":21},"2026-08-01",{"date":211,"type":21},"2026-12",{"name":39,"class":40},{"id":214,"slug":215,"hasResults":12,"nctId":216,"briefTitle":217,"officialTitle":218,"acronym":219,"eligibilityCriteria":220,"healthyVolunteers":139,"sex":17,"minAge":18,"maxAge":221,"enrollmentInfo":222,"targetDuration":4,"studyType":53,"phases":223,"briefSummary":224,"conditions":225,"keywords":229,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":233,"lastUpdatePostDateStruct":234,"startDateStruct":236,"completionDateStruct":238,"leadSponsor":240,"locationsCount":101},"100643987","independent-and-combined-effects-of-short-term-sulforaphane-supplementation-and-exercise-on-immunometabolism-in-healthy-adults-100643987","NCT07668596","Independent and Combined Effects of Short-term Sulforaphane Supplementation and Exercise on Immunometabolism in Healthy Adults","Independent and Combined Effects of Short-term Sulforaphane Supplementation and Exercise on Immunometabolism in Healthy Adults: A Randomized Crossover Study","EXSFN","Inclusion Criteria:\n\n* aged between 19 and 35 years\n* not a current smoker\n* physically active based on the Canadian Physical Activity Guidelines (150 minutes of weekly physical activity)\n\nExclusion Criteria:\n\n* a history of cardiometabolic diseases or respiratory diseases (e.g., chronic obstructive pulmonary disease, asthma, diabetes, coronary artery disease)\n* currently following a ketogenic diet\n* body mass index (BMI) over 30 kg\u002Fm2\n* unable to read or communicate in English\n* having received a vaccination or experienced an upper respiratory tract infection in the last 4 weeks\n* having donated more than 0.5 L of blood within the last 4 weeks\n* currently pregnant\n* have contraindications to high intensity exercise (assessed using the CSEP Get Active Questionnaire)","35 Years",{"count":194,"type":21},[113],"The study consist of 3 interventional periods which will be completed by each consenting participant in a randomized, crossover fashion. The interventional periods will be separated by a minimum 1 week washout period. One of the interventions consists of 4 days of daily supplementation with the commercially available broccoli sprout extract capsules (BrocElite). Another intervention will consist of 4 days of daily supervised treadmill running. The exercise protocol consists of 4 minutes of high-intensity running running followed by a 3 minute recovery period, repeated for a total of 4 repetitions. The last intervention combines the above two and consists of 4 days of daily supplementation and daily supervised exercise training. Before and after each intervention, basic anthropometrics (weight, heart rate, and blood pressure) will be recorded, and a venous blood sample will be collected. Blood samples will be analyzed for metabolic and inflammatory markers. Participants will be asked to refrain from structured exercise, alcohol consumption, and broccoli consumption during each of the experimental periods. Before any testing, willing participants will provide informed consent, and fill out a few demographic, and lifestyle questionnaires. The study will be conducted at the University of British Columbia in Kelowna, BC, Canada.",[226,227,228],"Immunometabolism","Mitochondrial Function, Bioenergetics","Inflammation",[230,204,231,226,228,232],"Nutraceuticals","Bioenergetics","High intensity interval training","2026-07-15",{"date":235,"type":33},"2026-07-17",{"date":237,"type":33},"2026-03-01",{"date":239,"type":21},"2028-06-01",{"name":39,"class":40},{"id":242,"slug":243,"hasResults":12,"nctId":244,"briefTitle":245,"officialTitle":246,"acronym":247,"eligibilityCriteria":248,"healthyVolunteers":12,"sex":17,"minAge":249,"maxAge":4,"enrollmentInfo":250,"targetDuration":4,"studyType":53,"phases":252,"briefSummary":253,"conditions":254,"keywords":266,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":274,"lastUpdatePostDateStruct":275,"startDateStruct":277,"completionDateStruct":279,"leadSponsor":281,"locationsCount":101},"100646109","evaluation-of-choose-to-move-replacement-ready-ctm-rr-100646109","NCT07696650","Evaluation of Choose to Move Replacement Ready (CTM-RR)","Choose to Move Replacement Ready: Implementation and Effectiveness of a Virtual Health-Promoting Intervention for People Awaiting Total Hip or Knee Replacement Surgery","CTM-RR","Inclusion Criteria:\n\n1. Activity coach hired by the Active Aging Society (activity coaches must speak English to participate in the evaluation);\n2. English-speaking older adults (aged \\>=50 years) who participate in CTM-RR will be invited to participate in the evaluation;\n3. Referral partner (People who work in a healthcare setting who refer patients into the program)\n\nExclusion Criteria:\n\n1. non-English speaking activity coach\n2. non-English speaking referral partner","50 Years",{"count":251,"type":21},210,[113],"Choose to Move (CTM) is a 3-month, choice-based health-promoting program for low active older adults being scaled-up across British Columbia (BC), Canada. Recently, the investigators adapted CTM for the \\>14000 people in BC who are on surgical waitlists for total knee replacement or total hip replacement (TKR\u002FTHR) for osteoarthritis (OA). The primary goals of this observational study are to describe how the adapted program, Choose to Move Replacement Ready (CTM-RR), is implemented in BC and determine if the adapted program improves health outcomes in people with hip and\u002For knee osteoarthritis who are on surgical waitlists for TKR\u002FTHR. The investigators will also evaluate whether any health benefits achieved by CTM-RR participants are maintained three months after they finish the program and also during the remaining time that they wait for their TKR\u002FTHR surgery.\n\nThe investigators will work with referral partners from hospitals and orthopaedic clinics in BC to recruit participants into CTM-RR. Participants who enrol in CTM-RR will answer online survey questions about the program and about their physical activity, mobility, pain, function, quality of life, willingness to undergo surgery, overall perception of their joint condition, psychosocial health, self-efficacy, social isolation, loneliness, and sedentary time. CTM-RR activity coaches will also answer online survey questions about the program. CTM-RR participants, activity coaches, and referral partners will also participate in interviews about the program.",[255,256,257,258,259,260,261,262,263,264,146,265],"Osteoarthritis (OA)","Osteoarthritis (OA) of the Hip","Osteoarthritis (OA) of the Knee","Total Knee Anthroplasty","Total Hip Arthroplasty (THA)","Mobility Limitation","Physical Activity","Older Adults","Social Isolation or Loneliness","Pain","Sedentary Behaviors",[267,122,268,269,270,271,272,273,264],"Osteoarthritis","Physical activity","Social isolation","Older adults","Mobility","Joint replacement","Loneliness","2026-07-08",{"date":276,"type":33},"2026-07-10",{"date":278,"type":21},"2026-08",{"date":280,"type":21},"2028-08",{"name":39,"class":40},{"id":283,"slug":284,"hasResults":12,"nctId":285,"briefTitle":286,"officialTitle":287,"acronym":4,"eligibilityCriteria":288,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":289,"targetDuration":4,"studyType":53,"phases":291,"briefSummary":292,"conditions":293,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":274,"lastUpdatePostDateStruct":296,"startDateStruct":297,"completionDateStruct":299,"leadSponsor":301,"locationsCount":302},"100646047","access-my-breast-cancer-care-app-100646047","NCT07696637","Access My Breast Cancer Care App","Access my Breast Cancer Care - Use of an eHealth App in Navigating the Breast Cancer Trajectory: A Randomized Controlled Trial","Inclusion Criteria:\n\n* You are at least 19 years of age (the team only treats adult patients)\n* You have a diagnosis of breast cancer, or a BRCA mutation, and will be -having breast surgery with reconstruction (the app is tailored the breast cancer journey)\n* You have access to a smartphone or computer (individuals participating in the study will require access to a smart phone or computer to access the application if randomized to the intervention group)\n* Must have basic reading skills in English (the app is only available in English language)\n\nExclusion Criteria:\n\n* You do not have access to a smartphone or computer (a computer or smart phone is required to access the application)\n* You are \\\u003C19 years of age (the team does not treat pediatric patients)\n* You do not have breast cancer or a BRCA mutation (the application is specific to the breast cancer journey)\n* You decline breast reconstruction (the application was designed by the plastics and reconstructive team, and with the app being in an infancy stage, the bulk of the content focuses on breast reconstruction surgery)\n* You are not able to read English (the app is only available in English language)",{"count":290,"type":21},148,[113],"The Access my Breast Cancer Care application was developed by a multidisciplinary team with the intention of providing breast cancer patients with a centralized area to navigate their journey. Several of the research team members (Dr. Macadam, Dr. Isaac, Selena (CNS) and Pauline (CNS)) provided clinical expertise to ensure accuracy of clinical content. The application houses educational resources, a calendar, symptom tracker, customizable care pathway, community forum and a chat feature. The study will be designed as a randomized controlled trial (RCT) to measure the effect of the application on patient-centered outcomes of 1) satisfaction with care 2) reduction in adverse events, 3) usability. The investigators will conduct focus groups to understand the benefit of the app from the patient perspective.",[294,295],"Breast Reconstruction","Breast Cancer",{"date":276,"type":33},{"date":298,"type":33},"2026-04-20",{"date":300,"type":21},"2027-09",{"name":39,"class":40},2,{"id":304,"slug":305,"hasResults":12,"nctId":306,"briefTitle":307,"officialTitle":308,"acronym":4,"eligibilityCriteria":309,"healthyVolunteers":139,"sex":17,"minAge":310,"maxAge":311,"enrollmentInfo":312,"targetDuration":4,"studyType":53,"phases":314,"briefSummary":315,"conditions":316,"keywords":318,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":323,"lastUpdatePostDateStruct":324,"startDateStruct":325,"completionDateStruct":327,"leadSponsor":329,"locationsCount":101},"100630778","leucine-requirements-in-school-age-children-100630778","NCT07492095","Leucine Requirements in School-Age Children","Determination of Leucine Requirements in Healthy School-Age Children Using the Indicator Amino Acid Oxidation Method","Inclusion Criteria:\n\n* Healthy children\n* Aged 6 to 10 years at enrollment\n* Body weight between the 3rd and 85th percentile according to WHO Child Growth Standards\n* Assent from the child and written informed consent from parent(s) and\u002For legal guardian(s)\n\nExclusion Criteria:\n\n* Diagnosis of any acute or chronic medical condition\n* Current use of prescription medication that may affect protein or energy metabolism\n* Recent weight loss\n* Recent illness (fever, vomiting, severe runny nose within the past 5 days)\n* Inability to comply with study procedures","6 Years","10 Years",{"count":313,"type":21},7,[113],"Leucine is an essential amino acid, which serves a special purpose of signaling cell growth in muscle in addition to making up protein. Essential amino acids like leucine need to be eaten every day from our foods like meat, dairy, eggs, beans, and nuts, as they cannot be made by our bodies. The current recommendation for leucine in the diet of school-age children are based upon adult needs. This study will measure the leucine requirement in children aged 6-10 years old using an non-invasive technique with special diets, safe stable isotopes, and simple breath collections. Creating guidelines based on measured requirements for leucine in this age group is essential for supporting optimal growth in healthy children.",[317],"Nutrient Intake",[319,320,321,322],"Leucine","School-Age Children","Amino Acid","Isotope","2026-07-06",{"date":274,"type":33},{"date":326,"type":33},"2026-06-25",{"date":328,"type":21},"2027-12-31",{"name":39,"class":40},{"id":331,"slug":332,"hasResults":12,"nctId":333,"briefTitle":334,"officialTitle":335,"acronym":336,"eligibilityCriteria":337,"healthyVolunteers":12,"sex":109,"minAge":18,"maxAge":4,"enrollmentInfo":338,"targetDuration":4,"studyType":53,"phases":339,"briefSummary":341,"conditions":342,"keywords":345,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":348,"lastUpdatePostDateStruct":349,"startDateStruct":351,"completionDateStruct":352,"leadSponsor":354,"locationsCount":4},"100646429","phase-4-study-of-hiv-exposed-pregnancies-and-transplacental-antibody-delivery-following-rsvpref-100646429","NCT07693166","Study of HIV-Exposed Pregnancies and Transplacental Antibody Delivery Following RSVpreF","Study of HIV-Exposed Pregnancies and Transplacental Antibody Delivery Following RSVpreF (SHIELD-RSV)","SHIELD-RSV","Inclusion Criteria:\n\n1. Pregnant women\u002Fpeople aged ≥19 years\n2. Confirmed diagnosis of HIV\n3. Gestational age between 28 and 34 weeks at enrollment (to allow scheduling of vaccination at 32-36 weeks)\n4. Able to provide informed consent\n\nExclusion Criteria:\n\n1. Contraindications to RSVpreF vaccine per product monograph\n2. History of severe allergic reaction to any vaccine component\n3. Planned delivery outside of British Columbia\n4. Received RSVpreF in current or previous pregnancy\n5. Received immunoglobulins (except Rh (D) immuneglobulin) within 1 year of enrollment\n6. Unable to complete in-person follow-up for infant at the Oak Tree Clinic",{"count":194,"type":21},[340],"PHASE4","Respiratory syncytial virus (RSV) is the leading cause of hospitalization in young infants in Canada. While most babies recover, RSV can cause severe breathing problems and place major stress on families and the health system. Infants born to pregnant women and people with HIV, even if they do not acquire the virus, face higher risks of RSV illness. This is partly because HIV increases the chance of preterm birth and can reduce the amount of protective antibodies passed to the baby during pregnancy.\n\nTwo new tools now exist to prevent RSV. One is a vaccine given in late pregnancy (RSVpreF), which boosts antibodies that cross the placenta and protect the baby at birth. The other is a long-lasting antibody (nirsevimab) given directly to infants after delivery. Both work well in the general population, but pregnant people living with HIV were excluded from the original studies. Health care providers therefore do not know if perinatal vaccination provides enough protection for these babies.\n\nThis study will follow 20 pregnant women\u002Fpeople with HIV at BC Women's Hospital who receive the RSVpreF vaccine. Antibody levels will be measured before and after vaccination from the pregnant recipient, and in infant blood sample, to see how well protection is transferred to infants. We will also assess vaccine safety, birth outcomes, and parental views on RSV immunization. Findings will guide Canadian policies to ensure that all infants, including those exposed to HIV, have equitable access to RSV protection.",[343,344],"RSV Immunization","HIV",[344,346,347],"RSVpreF","RSV","2026-07-03",{"date":350,"type":33},"2026-07-09",{"date":127,"type":21},{"date":353,"type":21},"2028-03-01",{"name":39,"class":40},{"id":356,"slug":357,"hasResults":12,"nctId":358,"briefTitle":359,"officialTitle":360,"acronym":4,"eligibilityCriteria":361,"healthyVolunteers":139,"sex":17,"minAge":310,"maxAge":362,"enrollmentInfo":363,"targetDuration":4,"studyType":53,"phases":365,"briefSummary":366,"conditions":367,"keywords":369,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":374,"lastUpdatePostDateStruct":375,"startDateStruct":377,"completionDateStruct":379,"leadSponsor":381,"locationsCount":101},"100643426","virtual-reality-for-pain-and-anxiety-in-pediatric-dental-treatment-100643426","NCT07636330","Virtual Reality for Pain and Anxiety in Pediatric Dental Treatment","Effects of Immersive Virtual Reality on Pain, Anxiety, and Post-Procedural Experience in Pediatric Dental Treatment: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Children aged 6 to 12 years\n* Scheduled for a routine invasive dental procedure\n* Accompanied by a parent or legal guardian\n* Parent\u002Fguardian able to provide written informed consent\n\nExclusion Criteria:\n\n* Children with visual or hearing impairments that would prevent use of the VR headset\n* Children with a history of motion sickness\n* Children with severe cognitive or developmental delays that would prevent completion of study measures\n* Children who have previously participated in this study\n* Children requiring emergency dental treatment","12 Years",{"count":364,"type":21},80,[113],"The goal of this clinical trial is to learn whether immersive virtual reality (VR) reduces pain and anxiety in children aged 6-12 years during routine dental procedures. The main questions it aims to answer are:\n\n* Does VR distraction reduce self-reported pain and anxiety during dental treatment compared to standard behaviour guidance?\n* Does VR distraction improve children's post-procedural experience and willingness to return for future dental visits?\n\nResearchers will compare children using a VR headset during dental treatment to children receiving standard behaviour guidance techniques.\n\nParticipants will:\n\n* Attend one routine dental appointment\n* Be randomly assigned to wear a VR headset or receive standard care during their procedure\n* Complete brief questionnaires about pain and anxiety before and after treatment\n* Receive a follow-up phone call 24-72 hours after the appointment",[368,264],"Dental Anxiety in Children",[370,119,371,372,373],"Distraction","Pediatric Dentistry","Dental Anxiety","Procedural Pain","2026-06-30",{"date":376,"type":33},"2026-07-02",{"date":378,"type":21},"2026-06-02",{"date":380,"type":21},"2027-06-30",{"name":39,"class":40},{"id":383,"slug":384,"hasResults":12,"nctId":385,"briefTitle":386,"officialTitle":387,"acronym":4,"eligibilityCriteria":388,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":389,"enrollmentInfo":390,"targetDuration":4,"studyType":53,"phases":391,"briefSummary":392,"conditions":393,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":395,"lastUpdatePostDateStruct":396,"startDateStruct":397,"completionDateStruct":399,"leadSponsor":400,"locationsCount":101},"100645039","6-weeks-of-blood-flow-restriction-training-on-immune-cell-function-and-bioenergetics-100645039","NCT07676305","6-Weeks of Blood Flow Restriction Training on Immune Cell Function and Bioenergetics","Impact of 6-Weeks of Blood Flow Restriction Training on Immune Cell Function and Bioenergetics in Adults withT2D","Inclusion Criteria:\n\nA. Aged 19-64 years. B. Diagnosed with type 2 diabetes with current HbA1c 5.7-9.0% C. Completing \\\u003C150 minutes of moderate-vigorous physical activity per week.\n\nExclusion Criteria:\n\nA. Chronic musculoskeletal condition or recent (within 2 years) cardiovascular event preventing participation in exercise.\n\nB. Unstable type 2 diabetes medication of the last 3 months C. Absolute contraindications to BFR (i.e., peripheral vascular disease) D. A self-reported diagnosis of low iron concentrations, anemia, or being treated for these conditions E. A diagnosis of any red blood cell-altering condition (i.e., sickle cell anemia, poikilocytosis) F. Currently living with any cardiovascular disease, which would impact the ability to participate in exercise safely G. Currently prescribed any medication which would impact the ability to use a heart rate monitor to accurately track intensity","64 Years",{"count":194,"type":21},[113],"To conduct a randomized control trial to determine the impact of 6-weeks of blood flow restriction training on immune cell function and bioenergetics in adults living with type 2 diabetes.",[394],"Type 2 Diabetes","2026-06-23",{"date":374,"type":33},{"date":398,"type":33},"2026-02-11",{"date":328,"type":21},{"name":39,"class":40},{"id":402,"slug":403,"hasResults":12,"nctId":404,"briefTitle":405,"officialTitle":406,"acronym":4,"eligibilityCriteria":407,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":408,"enrollmentInfo":409,"targetDuration":4,"studyType":53,"phases":411,"briefSummary":412,"conditions":413,"keywords":416,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":418,"lastUpdatePostDateStruct":419,"startDateStruct":421,"completionDateStruct":423,"leadSponsor":425,"locationsCount":101},"100644602","neuropathic-dental-pain--dbs-100644602","NCT07671950","Neuropathic Dental Pain & DBS","Pain Alleviation for Patients Receiving Directional Deep Brain Stimulation to Treat Neuropathic Dental Pain","Inclusion Criteria:\n\n* Age 19 to 80 years.\n* Diagnosis of Atypical Odontalgia (AO) (also known as neuropathic dental pain).\n* Receiving deep brain stimulation (DBS) treatment for AO due to inadequate response to conventional therapies, including: Pharmacological therapies, and\u002For Local anesthetics, corticosteroid injections, or nerve blocks.\n* Able and willing to provide informed consent.\n\nExclusion Criteria:\n\n* Refusal or inability to provide informed consent.\n* Known major depression.\n* Acute psychosis.","80 Years",{"count":410,"type":21},5,[113],"This prospective observational study will evaluate pain outcomes in patients with neuropathic dental pain (Atypical Odontalgia\u002FPhantom Tooth Pain) who undergo directional deep brain stimulation (DBS). Participants will complete validated pain, disability, quality-of-life, and mood assessments before surgery and following DBS programming. Directional stimulation will be applied to different thalamic targets to determine whether specific stimulation settings are associated with greater pain relief. The study aims to characterize changes in pain and quality of life following DBS and to identify the stimulation target associated with the greatest reduction in neuropathic dental pain.",[414,415],"Dental Neuralgia","Neuropathic Dental Pain",[415,414,417],"Deep Brain Stimulation","2026-06-22",{"date":420,"type":33},"2026-06-26",{"date":422,"type":33},"2026-01-01",{"date":424,"type":21},"2028-01-01",{"name":39,"class":40},{"id":427,"slug":428,"hasResults":12,"nctId":429,"briefTitle":430,"officialTitle":430,"acronym":431,"eligibilityCriteria":432,"healthyVolunteers":12,"sex":17,"minAge":433,"maxAge":434,"enrollmentInfo":435,"targetDuration":4,"studyType":53,"phases":437,"briefSummary":438,"conditions":439,"keywords":441,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":418,"lastUpdatePostDateStruct":447,"startDateStruct":448,"completionDateStruct":450,"leadSponsor":452,"locationsCount":4},"100644556","implementation-of-an-encounter-based-patient-decision-aid-for-heart-failure-medications-in-heart-function-clinics-the-share-hf-pragmatic-stepped-wedge-trial-100644556","NCT07670845","Implementation of an Encounter-based Patient Decision Aid for Heart Failure Medications in Heart Function Clinics: the SHARE-HF Pragmatic, Stepped-wedge Trial","SHARE-HF","Inclusion Criteria:\n\n1. Patient in a participating HF clinic;\n2. In-person initial HF clinic visit;\n3. Age 40-85 years;\n4. Heart failure with reduced ejection fraction (HFrEF), as indicated by latest cardiac imaging demonstrating ejection fraction ≤40%.\n\nExclusion Criteria:\n\n1. Previous request to the clinic not to be contacted for research;\n2. Consent opt-out;\n3. Non-BC residents;\n4. Residents of long-term care facilities or hospice;\n5. Receiving palliative care;\n6. End-stage kidney disease on dialysis or latest estimated glomerular filtration rate (eGFR) \\\u003C30 mL\u002Fmin\u002F1.73 m2.","40 Years","85 Years",{"count":436,"type":21},1350,[113],"The goal of this clinical trial is to learn if a shared decision-making tool called SHARE-HF can help more people with heart failure receive guideline-recommended medications. The study includes adults with a type of heart failure called heart failure with reduced ejection fraction (HFrEF), who attend heart function clinics in British Columbia, Canada. The main question it aims to answer is:\n\n\\- Does use of SHARE-HF during clinic visits lead to more participants receiving their recommended heart failure medications after 6 months?\n\nResearchers will compare clinics using the SHARE-HF tool to clinics providing usual care to see if the tool helps more participants get their recommended medications.\n\nParticipants will use the SHARE-HF web-based tool with their clinician during regular clinic visits. The tool shows participants how their heart failure may affect their health over time, explains their medication options, and helps them and their clinician make treatment decisions together.",[440],"Heart Failure With Reduced Ejection Fraction (HFrEF)",[442,443,444,445,446],"shared decision-making","decision aid","encounter-based decision aid","guideline-directed medical therapy","GDMT",{"date":420,"type":33},{"date":449,"type":21},"2026-11-02",{"date":451,"type":21},"2030-10-31",{"name":39,"class":40},{"id":454,"slug":455,"hasResults":12,"nctId":456,"briefTitle":457,"officialTitle":458,"acronym":459,"eligibilityCriteria":460,"healthyVolunteers":139,"sex":17,"minAge":4,"maxAge":461,"enrollmentInfo":462,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":463,"conditions":464,"keywords":467,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":472,"lastUpdatePostDateStruct":473,"startDateStruct":475,"completionDateStruct":477,"leadSponsor":479,"locationsCount":101},"100641572","infant-rsv-immunity-study-100641572","NCT07653347","Infant RSV Immunity Study","Understanding the Impact of Early-life RSV Infections on Infant Immunity and Long-term Health","IRIS","Inclusion Criteria:\n\nBirthing parent\u002Fchild pairs with a delivery date in April, May or June or September, October or November who delivered or are planning to deliver at BC Women's Hospital + Health Centre or a nearby, local hospital.\n\nExclusion Criteria:\n\nSevere pregnancy-related complications or chronic medical conditions in the children making them automatically eligible to receiving RSV immunoprophylaxis in British Columbia (e.g. infants born prematurely \\\u003C 35 weeks of gestation, or with chronic medical conditions).","6 Months",{"count":77,"type":21},"Respiratory Syncytial Virus (RSV) is a main global cause of respiratory illness and death in infants. Previous infant vaccine trials have failed to demonstrate protection. Moreover, RSV infection during early infancy, particularly in infants younger than 4 months of age, is associated with more severe disease, reduced immune protection, and an increased risk of developing childhood asthma. This study aim to investigate the immunological and long-term health effects of a first exposure to RSV early (\\\u003C4 months) versus late (\\>6-9 months) in infancy.",[465,466],"Respiratory Synctial Virus","Asthma Childhood",[468,469,470,471],"cohort study","Immune response","infants","season of birth","2026-06-11",{"date":474,"type":33},"2026-06-17",{"date":476,"type":33},"2026-01-15",{"date":478,"type":21},"2029-12-01",{"name":39,"class":40},{"id":481,"slug":482,"hasResults":12,"nctId":483,"briefTitle":484,"officialTitle":485,"acronym":4,"eligibilityCriteria":486,"healthyVolunteers":12,"sex":17,"minAge":487,"maxAge":488,"enrollmentInfo":489,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":491,"conditions":492,"keywords":494,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":501,"lastUpdatePostDateStruct":502,"startDateStruct":504,"completionDateStruct":506,"leadSponsor":508,"locationsCount":313},"100642528","smart-discharges-for-older-children-100642528","NCT07629154","Smart Discharges for Older Children","Smart Discharges for Older Children: A Cohort Study to Develop Prognostic Algorithms for Post-discharge Readmission and Mortality Among Children Over 5 Years of Age","Inclusion Criteria:\n\n* Age between 0 and 16 years admitted to pediatric ward of hospital for proven or suspected infection\n* Provide informed consent\n* Ability to provide contact information (phone number or address) for phone or in-person follow-up\n\nExclusion Criteria:\n\n* Child lives outside of the catchment area of a study site\n* Admitted for elective procedures, trauma, or short-term observation\n* Language barriers","5 Years","16 Years",{"count":490,"type":21},4000,"This study is an observational multi-country cohort study that aims to build algorithms that can identify children between 5 and 16 years of age admitted for proven or suspected sepsis who are at risk of mortality after they are discharged in East Africa.\n\nIn low- and middle-income countries, about 5% of children discharged after hospitalization for sepsis will die in the weeks after returning home. Doctors and parents are often unaware of this period of vulnerability and are poorly equipped to identify or handle this critical situation. This project builds on past work that developed and evaluated models and the Smart Discharges program to predict, during hospitalization, an individual child's risk of recurrent illness and mortality, as well as to provide additional post-discharge support to at-risk children.\n\nParticipants will be enrolled from facilities once they are admitted, collecting clinical and social variables. They will then be followed until 6 months post-discharge to understand what happens to them after they return home. This data will be evaluated to identify which variables collected at facilities can be predictive of mortality and recurrent illness after discharge.",[493],"Sepsis",[495,496,497,498,499,500],"pediatrics","sepsis","risk-prediction","critical care","post-discharge","patient discharge","2026-06-10",{"date":503,"type":33},"2026-06-15",{"date":505,"type":33},"2024-01-02",{"date":507,"type":21},"2027-04",{"name":39,"class":40},{"id":510,"slug":511,"hasResults":12,"nctId":512,"briefTitle":513,"officialTitle":513,"acronym":4,"eligibilityCriteria":514,"healthyVolunteers":12,"sex":17,"minAge":515,"maxAge":4,"enrollmentInfo":516,"targetDuration":4,"studyType":53,"phases":518,"briefSummary":519,"conditions":520,"keywords":523,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":524,"lastUpdatePostDateStruct":525,"startDateStruct":526,"completionDateStruct":528,"leadSponsor":530,"locationsCount":101},"100581189","rise--shine-promoting-sleep-quality-in-chronic-stroke-with-exercise-100581189","NCT06847074","Rise & Shine: Promoting Sleep Quality in Chronic Stroke With Exercise","Inclusion Criteria:\n\nWe will include community-dwelling adults who had an ischemic or hemorrhagic stroke at least one year prior to study enrolment and have poor sleep quality - defined as a sleep efficiency of \\\u003C or = 85%, with allowance for minor upward deviations on individual nights consistent with known night-to-night variability and instrument accuracy limits, and a PSQI global score of \\> 5. Individuals must also meet these inclusion criteria: 1) aged 55 years and older; 2) a baseline MMSE score of = or \\> 22\u002F30 and a MoCA score of = or \\> 19\u002F30; 3) community-dwelling; 4) able to comply with scheduled assessments, classes, and other trial procedures; 5) read, write, and speak English with acceptable visual and auditory acuity; 6) not to start or stable (i.e., = or \\> 6 months) on a fixed dose of medication that impacts sleep (i.e., anti-arrhythmics, beta blockers, selective serotonin reuptake inhibitor, etc.) during the 26-week intervention period; 7) able to walk for a minimum of six metres with rest intervals with or without assistive devices; 8) based on interview, have an activity tolerance of 60 minutes with rest intervals; 9) not participating in any regular therapy or progressive exercise (e.g., treadmill or weight-lifting); and 10) able to safely engage in exercise as indicated by the PAR-Q+63 and written confirmation by family or study physicians.\n\nExclusion Criteria:\n\nWe will exclude individuals who: 1) are diagnosed with OSA and are not using CPAP or defined as potentially having undiagnosed OSA (AHI \\> 20) as a result of study screening; 2) have restless leg syndrome; 3) are diagnosed with dementia of any type; 4) are diagnosed with another type of neurodegenerative or neurological condition (e.g., Parkinson's disease); 5) are planning to participate, or already enrolled in, a clinical drug trial or exercise trial concurrent to this study; 6) are at high risk for cardiac complications during exercise and\u002For unable to self-regulate activity or to understand recommended activity level; 7) have clinically significant peripheral neuropathy or severe musculoskeletal or joint disease that impairs mobility, as determined by his\u002Fher physician; or 8) have aphasia as judged by an inability to communicate by phone.","55 Years",{"count":517,"type":21},62,[113],"health problems, such as heart disease, diabetes, cognitive impairment, and dementia.\n\nAfter a person suffers a stroke, they often experience difficulties in getting a good night's sleep. Approximately half of stroke survivors have insomnia, or have trouble falling and\u002For staying asleep. Poor sleep quality among stroke survivors increases the risk of recurrent stroke by 3-fold and the risk of early death by 76%. Hence, stroke survivors need strategies to promote better sleep.\n\nFortunately, evidence shows that sleep quality can be improved with exercise, even among those who struggle with insomnia. Whether exercise training can improve sleep quality in adults with chronic stroke (i.e., at least 12 months has passed since their stroke) and poor sleep quality is not known. In addition, it is unknown if improved sleep is associated with improved outcomes in those with chronic stroke.\n\nThis study will specifically evaluate the effect of twice-weekly targeted exercise training on sleep quality over a 6-month period in persons with chronic stroke and poor sleep quality. This study will also evaluate the effect of exercise on the following outcomes: 1) sleep structure; 2) fatigue; 3) daytime sleepiness; 4) mood; 5) physical function and capacity; 6) thinking abilities; 7) heart health; and 8) quality of life. Finally, this study will examine how changes in sleep quality may be related to changes in these outcomes. Our proposed research is timely as the importance of sleep to recovery, health, and wellbeing post-stroke is increasingly recognized.",[521,522],"Stroke","Poor Quality Sleep",[204],"2026-06-08",{"date":472,"type":33},{"date":527,"type":33},"2025-05-15",{"date":529,"type":21},"2028-06-30",{"name":39,"class":40},{"id":532,"slug":533,"hasResults":12,"nctId":534,"briefTitle":535,"officialTitle":536,"acronym":537,"eligibilityCriteria":538,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":539,"enrollmentInfo":540,"targetDuration":4,"studyType":53,"phases":542,"briefSummary":543,"conditions":544,"keywords":546,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":548,"lastUpdatePostDateStruct":549,"startDateStruct":550,"completionDateStruct":552,"leadSponsor":554,"locationsCount":101},"100642951","using-breath-tests-to-study-gut-sulfur-changes-during-dietary-therapy-100642951","NCT07640659","Using Breath Tests to Study Gut Sulfur Changes During Dietary Therapy","Sulfur on the Breath: Using Breath Biomarkers to Monitor Gut Microbial Sulfur Metabolism During Elemental and Reduced Sulfur Dietary Therapy","Sulfur-UC","Inclusion Criteria:\n\n* Age 19-70 years.\n\n  =Diagnosis of mild-to-moderate ulcerative colitis, defined by a partial Mayo score (pMayo) of 2-7.\n* Evidence of active inflammation at enrollment, defined as:\n* C-reactive protein (CRP) \\> 5 mg\u002FL; or\n* Fecal calprotectin (FCP) \\> 200 µg\u002Fg.\n* Receiving stable medical therapy for ulcerative colitis for at least 8 weeks prior to enrollment.\n* No corticosteroid use at the time of recruitment.\n* Under consideration by the treating physician for treatment escalation or biologic switch due to inadequate response to current therapy.\n\nExclusion Criteria:\n\n* Partial Mayo score (pMayo) \\> 7.\n* Pregnant or breastfeeding.\n* Body mass index (BMI) \\\u003C 18 kg\u002Fm².\n* History of an eating disorder.\n* Severe psychiatric disorder.\n* Severe medical conditions, including:\n* Active cancer;\n* Significant cardiovascular disease;\n* Diabetes mellitus; or\n* Severe food allergies.\n* Known allergy or intolerance to corn, dextrose, or maltodextrin.\n* Antibiotic use within 3 months prior to enrollment.\n* Probiotic use within 3 months prior to enrollment.\n* Use of herbal anti-inflammatory supplements during the study period, including but not limited to:\n* Serrapeptidase;\n* Curcumin;\n* Boswellia; or\n* Bromelain.\n* History of major gastrointestinal surgery, including:\n* Ostomy;\n* Total colectomy; or\n* Short bowel syndrome.\n* Inability or unwillingness to comply with study procedures, including anticipated travel or other commitments that may interfere with participation.","70 Years",{"count":541,"type":21},45,[113],"This study aims to test whether a short liquid-based diet, followed by a low-sulfur eating plan, is safe, manageable, and helpful for people with mild to moderate ulcerative colitis. Investigators want to see if this approach can improve gut health, lower inflammation, and reduce symptoms. Investigators will also test breath samples as an easy, non-invasive way to track gut bacteria activity and disease changes. Investigators believe this diet plan can reduce harmful gut bacteria that produce irritating sulfur compounds, leading to better gut health and measurable improvements that can be detected through breath testing.",[545],"Ulcerative Colitis (UC)",[547],"Ulcerative colitis","2026-06-05",{"date":472,"type":33},{"date":551,"type":21},"2026-06-01",{"date":553,"type":21},"2029-12-31",{"name":39,"class":40},{"id":556,"slug":557,"hasResults":12,"nctId":558,"briefTitle":559,"officialTitle":560,"acronym":4,"eligibilityCriteria":561,"healthyVolunteers":12,"sex":109,"minAge":221,"maxAge":4,"enrollmentInfo":562,"targetDuration":4,"studyType":53,"phases":564,"briefSummary":565,"conditions":566,"keywords":569,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":551,"lastUpdatePostDateStruct":573,"startDateStruct":575,"completionDateStruct":577,"leadSponsor":579,"locationsCount":580},"100638505","preventing-ovarian-cancer-through-opportunistic-salpingectomy-at-the-time-of-laparoscopic-cholecystectomy-100638505","NCT07625137","Preventing Ovarian Cancer Through Opportunistic Salpingectomy at the Time of Laparoscopic Cholecystectomy","Expanding Opportunistic Bilateral Salpingectomy to Laparoscopic Cholecystectomy to Prevent Ovarian Cancer: A Feasibility and Safety Trial","Inclusion Criteria:\n\n* Individuals with fallopian tubes who are undergoing lap chole and have more than 24 hours from surgeon consult to surgery, regardless of menopausal status\n* Age of 35 years and older\n* Patient must be able to give oral and written informed consent\n* Premenopausal patients will be included but will be counseled regarding their fertility\n\nExclusion Criteria:\n\n* Less than 24 hours available from surgeon consult to surgery\n* Individuals with a desire for a future pregnancy\n* Previously had a salpingectomy or salpingo-oophorectomy",{"count":563,"type":21},240,[113],"This study aims to evaluate the feasibility, safety, and cost-effectiveness of opportunistic salpingectomy (OS-the removal of the fallopian tubes) at the time of laparoscopic cholecystectomy (the removal of the gallbladder) to prevent ovarian cancer. Ovarian cancer is the fifth leading cause of cancer-related mortality in females in Canada. OS can prevent the most common and lethal type of ovarian cancer, high-grade serous carcinoma (HGSC). OS during gynecologic surgery (hysterectomy or instead of tubal ligation) is safe and effective. However, rates of hysterectomies and tubal sterilization are decreasing. This research team aims to extend the prevention of ovarian cancer by expanding to offer OS during other surgeries in the abdomen, when patients are already undergoing a surgical procedure. This study will examine: 1) the feasibility of OS at the time of laparoscopic cholecystectomy; 2) the safety of OS at the time of laparoscopic cholecystectomy; 3) any health services consequences of offering OBS during laparoscopic cholecystectomy.\n\nThe hypothesis is that OS at the time of laparoscopic cholecystectomy is a feasible, safe, and cost-effective primary prevention strategy for ovarian cancer. It is also hypothesized that there will be 10-20 minutes of additional operating room time for completing OS, and that integrating the identified partners and knowledge users, as well as adding relevant knowledge users as the project progresses, will affect the rapid mobilization of our findings.",[567,568],"Salpingectomy","Laparoscopic Cholecystectomy",[567,570,571,572,568],"Ovarian Neoplasms","Primary prevention","Cholecystectomy",{"date":574,"type":33},"2026-06-04",{"date":576,"type":21},"2026-07-01",{"date":578,"type":21},"2029-03-02",{"name":39,"class":40},3,{"id":582,"slug":583,"hasResults":12,"nctId":584,"briefTitle":585,"officialTitle":586,"acronym":587,"eligibilityCriteria":588,"healthyVolunteers":12,"sex":17,"minAge":50,"maxAge":4,"enrollmentInfo":589,"targetDuration":4,"studyType":53,"phases":591,"briefSummary":592,"conditions":593,"keywords":596,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":600,"lastUpdatePostDateStruct":601,"startDateStruct":603,"completionDateStruct":604,"leadSponsor":606,"locationsCount":101},"100599867","evaluating-treatment-strategies-for-p53-mutant-oral-cancer-and-oral-cancer-precursors-100599867","NCT07090070","Evaluating Treatment Strategies for p53 Mutant Oral Cancer and Oral Cancer Precursors","Evaluating Treatment Strategies for p53 Mutant Oral Epithelial Dysplasia and SCC Study","p53 RCT","Inclusion Criteria:\n\n* Adults age 18 or over\n* No history of head and neck radiation\n* p53-abnormal IHC patterns (surrogate marker for TP53 mutation)\n\nCohort 1:\n\n* Biopsy-confirmed mild\u002Fmoderate dysplasia\n\nCohort 2:\n\n* Biopsy-confirmed severe dysplasia or CIS\n\nCohort 3:\n\n* T1 SCC with depth of Invasion (DOI) \\\u003C4mm\n* Clinically and radiologically node-negative (confirmed by contrast-enhanced CT)\n\nExclusion Criteria:\n\n* Immunocompromised status\n* Lesions greater than 3 cm\n* Presence of Proliferative Verrucous Leukoplakia\n\nCohort 1:\n\n* Had prior treatment for oral premalignant lesions\n\nCohort 2:\n\n* Presence of invasive SCC on initial biopsy\n\nCohort 3:\n\n* Positive nodes on contrast-enhanced CT\n* DOI \\>= 4mm",{"count":590,"type":21},636,[113],"The goal of this clinical trial is to optimize treatment strategies for patients with p53-mutant oral epithelial dysplasia (OED) and early-stage oral squamous cell carcinoma (OSCC). The main question it aims to answer is what the most optimal treatment is at each diagnostic stage. It is hypothesized that lesions with p53-abnormal low-grade dysplasia (LGD) without surgical intervention will progress to high-grade dysplasia (HGD) or SCC in 4 years. It is also predicted that a clear p53 and severe\u002FCIS excision margins in patients with p53-abnormal HGD will reduce the progression to invasive SCC, compared to clear severe\u002FCIS margins, within 4 years. Finally, it is thought that patients with p53-abnormal cT1N0 and DOI\\\u003C4mm receiving an END will have improved disease free and overall survival. This research will elucidate whether or not these hypotheses are correct.\n\nParticipants in each diagnostic cohort will be assigned to one of two different treatment options, listed below:\n\nCohort 1:\n\nA) No intervention, observation only B) Surgical excision with clear margins\n\nCohort 2:\n\nA) Surgical excision with clear severe\u002FCIS margins B) Surgical excision with clear severe\u002FCIS and p53 margins\n\nCohort 3:\n\nA) Surgical excision and elective neck dissection (END) B) Surgical excision and close follow-up, only salvage ND if development of nodal disease",[594,595],"Oral Epithelial Dysplasia (OED)","Oral Squamous Cell Carcinoma (SCC)",[597,598,599],"p53 mutant","SCC","oral epithelial dysplasia","2026-05-29",{"date":602,"type":33},"2026-06-03",{"date":551,"type":21},{"date":605,"type":21},"2032-09",{"name":39,"class":40},{"id":608,"slug":609,"hasResults":12,"nctId":610,"briefTitle":611,"officialTitle":611,"acronym":612,"eligibilityCriteria":613,"healthyVolunteers":12,"sex":17,"minAge":50,"maxAge":614,"enrollmentInfo":615,"targetDuration":4,"studyType":53,"phases":617,"briefSummary":618,"conditions":619,"keywords":622,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":600,"lastUpdatePostDateStruct":624,"startDateStruct":625,"completionDateStruct":627,"leadSponsor":629,"locationsCount":630},"100589592","rehabilitation-of-memory-symptoms-after-brain-concussion-100589592","NCT06956417","REhabilitation of MEMory Symptoms After BRain Concussion","REMEMBR","Inclusion Criteria:\n\n1. Age 18-59\n2. Concussion diagnosis confirmed with structured interview based on American Congress of Rehabilitation Medicine diagnostic criteria\n3. Concussion occurred between 6 and 36 months before enrollment\n4. Ongoing memory concerns\n5. Fluent in English\n6. Stable access to a computer, tablet, or smartphone with internet capability\n\nExclusion Criteria:\n\n1. Fail performance validity testing\n2. Comorbid psychiatric or neurological disorder or is taking a medication that could fully account for their memory symptoms","59 Years",{"count":616,"type":21},184,[113],"Persistent memory symptoms after concussion are common, and likely perpetuated by unhelpful illness beliefs and coping behaviors. Results from a pilot study suggested that traditional cognitive rehabilitation and a novel cognitive-behavioral therapy (CBT) protocol were both associated with improvements in subjective memory functioning. The present study will more definitively compare the effectiveness of these interventions for improving subjective memory functioning after concussion.",[620,621],"Concussion, Brain","Mild Traumatic Brain Injury",[623],"Functional cognitive disorder",{"date":378,"type":33},{"date":626,"type":33},"2025-07-02",{"date":628,"type":21},"2029-04-30",{"name":39,"class":40},8,{"id":632,"slug":633,"hasResults":12,"nctId":634,"briefTitle":635,"officialTitle":636,"acronym":637,"eligibilityCriteria":638,"healthyVolunteers":12,"sex":17,"minAge":249,"maxAge":4,"enrollmentInfo":639,"targetDuration":4,"studyType":53,"phases":641,"briefSummary":642,"conditions":643,"keywords":645,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":600,"lastUpdatePostDateStruct":649,"startDateStruct":650,"completionDateStruct":652,"leadSponsor":654,"locationsCount":101},"100535387","a-multi-centre-study-of-shoe-worn-insoles-and-knee-osteoarthritis-100535387","NCT06251167","A Multi-centre Study of Shoe-worn Insoles and Knee Osteoarthritis","A Multi-centre Feasibility Study Assessing Shoe-worn Insoles to Improve Clinical and Biomechanical Features of Knee Osteoarthritis","MULTIWEDGE","Inclusion Criteria:\n\n* medial tibiofemoral OA defined as definitive osteophytes and joint space narrowing in the medial compartment, as confirmed with radiographs\n* history of knee pain longer than 6 months\n* average self-reported knee pain of at least 3 out of 10 (using an 11-point numerical rating scale with terminal descriptors of 0 = \"no pain\" and 10 = \"worst pain imaginable\") over the 6 months prior to baseline testing\n* pain in the same foot\u002Ffeet as the painful knee(s)\n* ability to communicate in English\n* show an immediate biomechanical response to the insoles. This final eligibility criterion will be determined from an in-person biomechanical assessment after participants have passed all previous eligibility screening.\n\nExclusion Criteria:\n\n* radiographic evidence of more lateral tibiofemoral OA than medial\n* knee surgery or intra-articular injection within the previous 6 months\n* current or recent (within 6 months) corticosteroid use for any reason\n* presence of a systemic arthritic condition\n* history of knee joint replacement or tibial osteotomy\n* any other condition affecting lower limb function\n* current usage of shoe-worn insoles, or planning to acquire footwear modifications in the next 6 months\n* any previous experience with insoles that resulted in increased lower limb pain or a self- or clinician-initiated termination of use.",{"count":640,"type":21},31,[113],"Shoe-worn insoles (also known as orthotics) can provide symptomatic relief for people with knee osteoarthritis. However, given they act at the feet, and given that many people with knee osteoarthritis also report foot pain, it is important to assess the effects of these devices at both joints. We will conduct a multi-centre randomized pilot trial to determine feasibility and preliminary efficacy.",[644],"Knee Osteoarthritis",[644,646,647,648],"Orthotics","Foot pain","Biomechanics",{"date":551,"type":33},{"date":651,"type":33},"2024-03-04",{"date":653,"type":21},"2027-04-10",{"name":39,"class":40},{"id":656,"slug":657,"hasResults":12,"nctId":658,"briefTitle":659,"officialTitle":660,"acronym":661,"eligibilityCriteria":662,"healthyVolunteers":12,"sex":17,"minAge":50,"maxAge":4,"enrollmentInfo":663,"targetDuration":4,"studyType":53,"phases":665,"briefSummary":666,"conditions":667,"keywords":670,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":672,"lastUpdatePostDateStruct":673,"startDateStruct":674,"completionDateStruct":676,"leadSponsor":678,"locationsCount":101},"100472224","mandibular-reconstruction-preplanning-vipmr-100472224","NCT05429099","Mandibular Reconstruction Preplanning (ViPMR)","Virtual Preplanning of Mandibular Reconstruction (ViPMR): a Phase III Randomized Controlled Clinical Trial","ViPMR","Inclusion Criteria:\n\n* primary diagnosis requiring mandibulectomy and fibular or scapular free flap reconstructive surgery\n* are over the age of 18\n* cognitive ability and language skills that allow participation in the trial\n* provide informed consent\n\nExclusion Criteria:\n\n* severe comorbidities including metastatic disease\n* do not have a recent (within 30 days) CT scan and are unable\u002Funwilling to receive a head CT scan at the latest 6 days prior to surgery\n* prior history of head or neck cancer within last 5 years\n* prior history of head or neck radiation treatment at any time\n* pregnant of lactating women",{"count":664,"type":21},420,[113],"Virtual Surgical Planning (VSP), where 3D modeling is used to create 3D-printed surgical guides, has been shown to improve outcomes for patients who undergo mandibular reconstruction surgery, usually due to invasion of cancer from the oral cavity to the jaw. This trial will directly compare the outcomes of patients who receive VSP versus patients who receive the current standard of care, which is Free-Hand Surgery (FHS). They will be randomized into either treatment at a 1:1 ratio and bony union rates will be compared between 12-month postoperative CT scans for each treatment group. Secondary objectives include comparing other short and long-term complication rates, reconstruction accuracy, quality of life, and functional outcomes of VSP and FHS. An economic analysis of VSP will also be performed.",[668,669],"Oral Cavity Cancer","Oral Cancer",[668,669,671],"Mandibular Reconstruction","2026-05-28",{"date":551,"type":33},{"date":675,"type":33},"2022-10-15",{"date":677,"type":21},"2028-10-15",{"name":39,"class":40},""]